Comparative study on altered hepatic metabolism of CYP3A substrates in rats with glycerol-induced acute renal failure

2012 ◽  
Vol 33 (1) ◽  
pp. 22-29 ◽  
Author(s):  
Jun-ichi Kusaba ◽  
Noriko Kajikawa ◽  
Hiromu Kawasaki ◽  
Yuji Kurosaki ◽  
Tetsuya Aiba
Pharmaceutics ◽  
2020 ◽  
Vol 12 (8) ◽  
pp. 714
Author(s):  
Sung Hun Bae ◽  
Sun-Young Chang ◽  
So Hee Kim

Tofacitinib is a Jak inhibitor developed as a treatment for rheumatoid arthritis. Tofacitinib is metabolized mainly through hepatic CYP3A1/2, followed by CYP2C11. Rheumatoid arthritis tends to increase renal toxicity due to drugs used for long-term treatment. In this study, pharmacokinetic changes of tofacitinib were evaluated in rats with gentamicin (G-ARF) and cisplatin-induced acute renal failure (C-ARF). The time-averaged total body clearance (CL) of tofacitinib in G-ARF and C-ARF rats after 1-min intravenous infusion of 10 mg/kg was significantly decreased by 37.7 and 62.3%, respectively, compared to in control rats. This seems to be because the time-averaged renal clearance (CLR) was significantly lower by 69.5 and 98.6%, respectively, due to decreased creatinine clearance (CLCR). In addition, the time-averaged nonrenal clearance (CLNR) was also significantly lower by 33.2 and 57.4%, respectively, due to reduction in the hepatic CYP3A1/2 and CYP2C11 subfamily in G-ARF and C-ARF rats. After oral administration of tofacitinib (20 mg/kg) to G-ARF and C-ARF rats, both CLR and CLNR were also significantly decreased. In conclusion, an increase in area under plasma concentration-time curves from time zero to time infinity (AUC) of tofacitinib in G-ARF and C-ARF rats was due to the significantly slower elimination of tofacitinib contributed by slower hepatic metabolism and urinary excretion of the drug.


Renal Failure ◽  
1997 ◽  
Vol 19 (1) ◽  
pp. 111-120 ◽  
Author(s):  
Rinaldo Bellomo ◽  
John Seacombe Bapplsci ◽  
Michael Daskalakis ◽  
Michael Farmer ◽  
Christopher Wright ◽  
...  

2012 ◽  
Vol 1 (2) ◽  
pp. 100-106 ◽  
Author(s):  
Bal Kishan Gupta ◽  
Kailash Chandra Nayak ◽  
Sunil Kumar ◽  
Surendra Kumar ◽  
Anjli Gupta ◽  
...  

2009 ◽  
Vol 24 (5) ◽  
pp. 451-457 ◽  
Author(s):  
Yuki Izuwa ◽  
Jun-ichi Kusaba ◽  
Mizuki Horiuchi ◽  
Tetsuya Aiba ◽  
Hiromu Kawasaki ◽  
...  

2017 ◽  
Vol 12 (2) ◽  
pp. 79-82
Author(s):  
Nicolae GRIGORE ◽  
◽  
Valentin PIRVUT ◽  
Ionela MIHAI ◽  
Adrian HASEGAN ◽  
...  

Despite the modern advancement in endourology, percutaneous nephrostomy play an important role in many urologic conditions, which of the most important is the relief of upper urinary tract in patients with malignancies that interests the ureter or the uretero-vesical junction. The aim of the study is to compare the complications of polyurethane and silicone catheters used for percutaneous nephrostomy in patients with unilateral or bilateral uretero-hydronephrosis secondary to locally advanced abdomino-pelvin malignancies. We have retrospective analyzed 164 patients (p), admitted between January 2013 and December 2016 in Urology Department Sibiu, who benefit from unilateral or bilateral percutaneous nephrostomy for secondary uretero-hydronephrosis with acute renal failure.


Sign in / Sign up

Export Citation Format

Share Document